| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -25,130 | -30,150 | -39,750 | -93,060 | -430 |
| Net Income Growth | +16.65% | +24.15% | +57.29% | -21,541.86% | -204.88% |
Nrx Pharmaceuticals Inc (NRXP)
2.07 x 2 2.15 x 1
Post-market by (Cboe BZX)
2.05 +0.02 (+0.99%) 03/31/25 [NASDAQ]
2.07 x 2 2.15 x 1
Post-market 2.05 unch (unch) 16:00 ET
for Mon, Mar 31st, 2025
NRX Pharmaceuticals Inc. is a patient-focused, clinical stage pharmaceutical company. It creates therapies to treat diseases where no medicines currently exist. NRX Pharmaceuticals Inc., formerly known as Big Rock Partners Acquisition Corp., is based in RADNOR, Pa.
Fiscal Year End Date: 12/31